Martin Fellermeyer

Final year PhD student focusing on cancer immunotherapy and antibody engineering @DavisLab_Oxford @UniofOxford.

[MRC TIDU @MRC_TIDU]

NEW: @ImmunityCP study from the @DavisLab_Oxford, @CornallLab and @KlenermanLab uncovers how antibodies trigger immune receptors & provides a framework for designing better therapeutic antibodies for cancer & autoimmune diseases.

Read the full story here: https://t.co/4uE7Karrzx

[Edward Jenkins @DrEdJenks]

Got a big itch to study T-cell exhaustion!!??

Our review has got your back! We include:

🙆The latest updates in exhaustion🙆
🧪In vivo/vitro models of exhaustion🧪
📊How to best verify in vitro exhausted T cells📊
📈The future of in vitro approaches📈

https://t.co/bKzNnfBS6E

[Martin Fellermeyer @MFellermeyer]

Thanks to the WIMM Postdoc Association for organising this symposium!

[MRC WIMM @MRC_WIMM]

Congratulations to the winners of the audience-voted awards at the @MRC_WIMM Postdoc Symposium yesterday:

🎉Best Scientific Report: Andrew McIntyre (@ChakravertyLab)

🌟Best Introductory Flash Talk: @MFellermeyer (@DavisLab_Oxford)
⚡️Runner Up: Li-Hsin Chang (@jdavieslab)

[Immunotherapy Advances Journal @IMTadvances]

Researchers at @DavisLab_Oxford investigate the potential of a new combination #immunotherapy of #nivolumab, a clinically approved #PD1 blocking antibody, & OX108, a #CD200R blocker

Explore their results in mouse models for colorectal & lung #cancer ➡️https://t.co/MV44mMN76W

[Martin Fellermeyer @MFellermeyer]

Very pleased to have my first PhD publication published in @IMTadvances. Using humanised mice we trialled the combination immunotherapy of nivolumab and OX108 (a CD200R blocker) in two tumour models.
@DavisLab_Oxford @CornallLab @MRC_HIU @MRC_WIMM @RDMOxford

[Immunotherapy Advances Journal @IMTadvances]

Our latest article explores the potential of a combination #immunotherapy comprising #Nivolumab, a clinically approved #PD1 blocking antibody, & OX108, a CD200R antagonist, in mouse models for colorectal & lung #cancer

Explore the results ➡️https://t.co/iRDjWIan1b